Form 4: Jazz Pharmaceuticals Director Trades Ordinary Shares
Statement of Changes in Beneficial Ownership
Jazz Pharmaceuticals Director Bruce C. Cozadd reported a transaction involving the acquisition of 6,000 ordinary shares on May 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Bruce C. Cozadd, a Director at Jazz Pharmaceuticals plc, reported a transaction on May 1, 2026.
- The transaction involved the acquisition of 6,000 ordinary shares.
- The acquisition was made at a price of $203.33 per share.
- Following this transaction, Mr. Cozadd beneficially owns 378,682 ordinary shares directly.
- This transaction was executed under a Rule 10b5-1 trading plan adopted on November 26, 2025, indicating it was not a discretionary trade.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing. While director share acquisitions can be positive, the transaction was pre-planned and automatic under a Rule 10b5-1 plan, limiting its interpretative value as a discretionary vote of confidence.
Positives
- The transaction was conducted under a Rule 10b5-1 plan, which is designed to provide an affirmative defense against allegations of insider trading, suggesting adherence to good governance practices.
- The acquisition of shares by a director can be interpreted as a positive signal of confidence in the company's future prospects.
Future Outlook
The filing itself does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports a past transaction.
Industry Context
StockSavvy.ai notes that Form 4 filings, particularly those involving director transactions under Rule 10b5-1 plans, are standard disclosures in the pharmaceutical and biotechnology sectors. These filings provide transparency into insider activity and are closely monitored by investors for signals of management's confidence in the company's valuation and prospects.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Rule 10b5-1 Trading Plan | The transaction was executed under a pre-arranged trading plan adopted by the reporting person, designed to comply with Rule 10b5-1(c) of the Securities Exchange Act of 1934. | 11/26/2025 | Demonstrates adherence to established corporate governance protocols for insider stock transactions, mitigating potential conflicts of interest and insider trading concerns. |
Stakeholder Impact
- Shareholders: The acquisition by a director may be viewed positively, suggesting confidence in the company's value, though the pre-planned nature of the trade tempers this interpretation.
- Management: Reinforces the importance of adhering to regulatory requirements and established trading plans for insider transactions.
Key Dates
| Date | Description |
|---|---|
| 11/26/2025 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 05/01/2026 | Date of the transaction (acquisition of ordinary shares). |
| 05/05/2026 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Rule 10b5-1, Director Transaction, Ordinary Shares, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.